The company was created by Stemline Therapeutics (formerly NASDAQ: STML) management, a veteran team with a proven track record of clinical and regulatory achievement, including FDA and EMA approval and the successful commercial launch of ELZONRIS®, an FDA-designated breakthrough therapy. LX-101 has a differentiated mechanism of action, consisting of a proprietary, precision-engineered IGF-1 variant with high affinity to IGF-1R, coupled to methotrexate, a cytotoxic inhibitor used to treat certain cancers and autoimmune diseases including TED.
Cyborg Score Rationale
Lirum is a well-capitalized, early-stage biotech with experienced management from successful biopharma exits, a focused pipeline with a differentiated lead candidate showing clinical promise, and expanding clinical development across multiple indications. However, early-stage development status and lack of FDA approvals create execution risk.
Top Insights
LX-101 received FDA 'Study May Proceed' letter in October 2025 enabling inclusion in RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
LX-101 data selected for presentation at major conferences in 2025 including AACR, ARVO, ESMO TAT, Gordon Research Conference, and NANOS, demonstrating expanding clinical evidence across oncology and autoimmune indications
Company founded in 2021 with 3 total employees
LX-101 has been clinically evaluated in Phase 1a trials of advanced, pretreated cancer patients where it was found to be well-tolerated and demonstrated single agent activity
Named Competitors
Cytokinetics — Biopharmaceutical company focused on muscle biology and cardiac therapeutics
Kiniksa Pharmaceuticals — Biopharmaceutical company developing immunology and autoimmune therapeutics
AMO Pharma — Biopharmaceutical company developing treatments for rare and debilitating diseases
Recent Developments
(October 2025) FDA Study May Proceed letter for LX-101 in Ewing Sarcoma and Desmoplastic Small Round Cell Tumor platform trial
(May 2025) LX-101 thyroid eye disease data selected for presentation at ARVO 2025 Annual Meeting
(April 2025) Positive LX-101 cancer data selected for presentation at AACR 2025 Annual Meeting
(March 2025) LX-101 presented at Gordon Research Conference and NANOS 2025 Annual Meeting
Open the full interactive Lirum Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.